A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Status: Recruiting
Location: See all (100) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Able and willing to sign the informed consent (IC)
• Patients with a diagnosis of AD and onset of disease for at least 1 year
• Moderate to severe AD
Locations
United States
Alabama
Novartis Investigative Site
RECRUITING
Birmingham
Novartis Investigative Site
RECRUITING
Birmingham
Arkansas
Novartis Investigative Site
RECRUITING
Fort Smith
California
Novartis Investigative Site
RECRUITING
Fountain Valley
Novartis Investigative Site
RECRUITING
Los Angeles
Novartis Investigative Site
RECRUITING
Sacramento
Novartis Investigative Site
RECRUITING
Santa Ana
Novartis Investigative Site
RECRUITING
Santa Monica
Washington, D.c.
Novartis Investigative Site
RECRUITING
Washington D.c.
Florida
Novartis Investigative Site
RECRUITING
Miami
Novartis Investigative Site
RECRUITING
St. Petersburg
Georgia
Novartis Investigative Site
RECRUITING
Atlanta
Novartis Investigative Site
RECRUITING
Macon
Kentucky
Novartis Investigative Site
RECRUITING
Louisville
Massachusetts
Novartis Investigative Site
RECRUITING
Brighton
Michigan
Novartis Investigative Site
RECRUITING
Troy
Missouri
Novartis Investigative Site
RECRUITING
Saint Joseph
New Hampshire
Novartis Investigative Site
RECRUITING
Portsmouth
New York
Novartis Investigative Site
RECRUITING
Brooklyn
Texas
Novartis Investigative Site
RECRUITING
Arlington
Novartis Investigative Site
RECRUITING
Cypress
Novartis Investigative Site
RECRUITING
Dallas
Novartis Investigative Site
RECRUITING
Houston
Novartis Investigative Site
RECRUITING
San Antonio
Other Locations
Argentina
Novartis Investigative Site
RECRUITING
Caba
Novartis Investigative Site
RECRUITING
Caba
Novartis Investigative Site
RECRUITING
Rosario
Canada
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Edmonton
Novartis Investigative Site
RECRUITING
Hamilton
Novartis Investigative Site
RECRUITING
Markham
Novartis Investigative Site
RECRUITING
Montreal
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Verdun
China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Beijing
Novartis Investigative Site
WITHDRAWN
Beijing
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Changchun
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Changsha
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Guangzhou
Novartis Investigative Site
RECRUITING
Hangzhou
Novartis Investigative Site
RECRUITING
Shanghai
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Shantou
France
Novartis Investigative Site
RECRUITING
Brest
Novartis Investigative Site
RECRUITING
Lille
Novartis Investigative Site
RECRUITING
Lorient
Novartis Investigative Site
RECRUITING
Paris
Novartis Investigative Site
RECRUITING
Pierre-bénite
Novartis Investigative Site
RECRUITING
Reims
Novartis Investigative Site
RECRUITING
Rouen
Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Bad Bentheim
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Dresden
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Frankfurt Am Main
Novartis Investigative Site
RECRUITING
Hamburg
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Heidelberg
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Magdeburg
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Mainz
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Münster
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Oldenburg
Hungary
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Budapest
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Budapest
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Debrecen
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Pécs
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Szeged
Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Ancona
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Cona
Novartis Investigative Site
RECRUITING
Pisa
Japan
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Fukuoka
Novartis Investigative Site
RECRUITING
Habikino
Novartis Investigative Site
RECRUITING
Kawasaki
Novartis Investigative Site
RECRUITING
Kyoto
Novartis Investigative Site
RECRUITING
Matsudo
Novartis Investigative Site
RECRUITING
Nagoya
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Shinagawa Ku
Novartis Investigative Site
RECRUITING
Yokohama
Netherlands
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Rotterdam
Novartis Investigative Site
RECRUITING
Utrecht
Poland
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Katowice
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Lodz
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Lublin
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Warsaw
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Warsaw
Republic of Korea
Novartis Investigative Site
RECRUITING
Ansan
Novartis Investigative Site
RECRUITING
Seoul
Slovakia
Novartis Investigative Site
WITHDRAWN
Bardejov
Novartis Investigative Site
RECRUITING
Komárno
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Košice
Novartis Investigative Site
RECRUITING
Košice
Novartis Investigative Site
RECRUITING
Prešov
Spain
Novartis Investigative Site
RECRUITING
Alicante
Novartis Investigative Site
RECRUITING
Badalona
Novartis Investigative Site
RECRUITING
Granada
Novartis Investigative Site
RECRUITING
Las Palmas Gc
Novartis Investigative Site
RECRUITING
Madrid
Novartis Investigative Site
RECRUITING
Madrid
Novartis Investigative Site
RECRUITING
Pontevedra
Taiwan
Novartis Investigative Site
RECRUITING
Kaohsiung City
Novartis Investigative Site
RECRUITING
Taipei
Novartis Investigative Site
RECRUITING
Taipei
Novartis Investigative Site
RECRUITING
Taipei
United Kingdom
Novartis Investigative Site
SUSPENDED
Dudley
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Liverpool
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
London
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
1-888-669-6682
Backup
Novartis Pharmaceuticals
+41613241111
Time Frame
Start Date: 2025-05-16
Estimated Completion Date: 2028-12-22
Participants
Target number of participants: 224
Treatments
Experimental: GHZ339 Dose A
Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2
Experimental: GHZ339 Dose B
Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2
Experimental: GHZ339 Dose C
Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2
Experimental: GHZ339 Dose D
Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2
Placebo_comparator: Placebo
Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals